Checkpoint Therapeutics Statistics
Total Valuation
NPB has a market cap or net worth of $498.29 million. The enterprise value is $1.39 billion.
Important Dates
The last earnings date was Tuesday, July 22, 2025, after market close.
Earnings Date | Jul 22, 2025 |
Ex-Dividend Date | Jul 15, 2025 |
Share Statistics
NPB has 34.36 million shares outstanding. The number of shares has increased by 14.29% in one year.
Current Share Class | 30.39M |
Shares Outstanding | 34.36M |
Shares Change (YoY) | +14.29% |
Shares Change (QoQ) | +15.67% |
Owned by Insiders (%) | 37.41% |
Owned by Institutions (%) | 34.62% |
Float | 11.72M |
Valuation Ratios
The trailing PE ratio is 7.18 and the forward PE ratio is 5.63.
PE Ratio | 7.18 |
Forward PE | 5.63 |
PS Ratio | 2.06 |
Forward PS | 2.66 |
PB Ratio | 0.82 |
P/TBV Ratio | 0.83 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | 23.49 |
EV / Sales | 6.77 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | $409,424 |
Profits Per Employee | $118,076 |
Employee Count | 500 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, NPB has paid $21.23 million in taxes.
Income Tax | 21.23M |
Effective Tax Rate | 23.98% |
Dividends & Yields
This stock pays an annual dividend of $0.10, which amounts to a dividend yield of 0.68%.
Dividend Per Share | $0.10 |
Dividend Yield | 0.68% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 2.48% |
Buyback Yield | -14.29% |
Shareholder Yield | -13.60% |
Earnings Yield | 11.85% |
FCF Yield | n/a |
Dividend Details Analyst Forecast
The average price target for NPB is $17.75, which is 22.41% higher than the current price. The consensus rating is "Buy".
Price Target | $17.75 |
Price Target Difference | 22.41% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |